Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 2103-2106, 2006. First published September 21, 2006; 10.1373/clinchem.2006.070979
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 070979.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.070979v1
52/11/2103    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bouamrani, A.
Right arrow Articles by Berger, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bouamrani, A.
Right arrow Articles by Berger, F.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2006;52:2103-2106.)
© 2006 American Association for Clinical Chemistry, Inc.

Technical Briefs

Direct-Tissue SELDI-TOF Mass Spectrometry Analysis: A New Application for Clinical Proteomics

Ali Bouamrani1,1, Jessica Ternier1,2,1, David Ratel1, Alim-Louis Benabid1,2, Jean-Paul Issartel1, Elisabeth Brambilla3,2 and François Berger1,a,2

1 INSERM U318, Université de Grenoble
Departments of2 Neurosurgery and 3 Pathology, Centre Hospitalier Universitaire Grenoble

aaddress correspondence to this author at: Neuroscience moléculaire, INSERM U318, Pavillon B, Centre Hospitalier Universitaire BP 217, 38043 Grenoble cedex 9 France; fax 33-4-76-76-56-19; e-mail fberger{at}ujf-grenoble.fr


Abstract

Background: New molecular profiling technologies can aid in analysis of small pathologic samples obtained by minimally invasive biopsy and may enable the discovery of key biomarkers synergistic with anatomopathologic analysis related to prognosis, therapeutic response, and innovative target validation. Thus proteomic analysis at the histologic level in healthy and pathologic settings is a major issue in the field of clinical proteomics.

Methods: We used surface-enhanced laser desorption ionization-time-of-flight mass spectrometry (SELDI-TOF MS) technology with surface chromatographic subproteome enrichment and preservation of the spatial distribution of proteomic patterns to detect discrete modifications of protein expression. We performed in situ proteomic profiling of mouse tissue and samples of human cancer tissue, including brain and lung cancer.

Results: This approach permitted the discrimination of glioblastomas from oligodendrogliomas and led to the identification of 3 potential markers.

Conclusion: Direct tissue proteomic analysis is an original application of SELDI-TOF MS technology that can expand the use of clinical proteomics as a complement to the anatomopathological diagnosis.




The following articles in journals at HighWire Press have cited this article:


Home page
 Ther Adv Respir DisHome page
Xiangdong Wang
Editorial The significance of tissue-imaging proteomics in respiratory therapies
Therapeutic Advances in Respiratory Disease, December 1, 2007; 1(2): 81 - 83.
[PDF]

Home page
 Clin. Chem.Home page
R. Machaalani, M. Arlotto, K. A. Waters, E. Gozal, F. Berger, and M. Dematteis
A Novel Method of Tissue Collection and Storage: Validation Using SELDI-TOF MS Analysis
Clin. Chem., July 1, 2007; 53(7): 1387 - 1389.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.